It indicated that salmeterol xinafoate/MgIG drug combination could play a better synergistic effect to alleviate pulmonary inflammation and improve lung function of COPD rats by JAK/STAT pathway, and MgIG might be a potential clinical alternative adjuvant drug for fluticasone propionate in routine clinical drug combination of salmeterol xinafoate/fluticasone propionate for COPD treatment (Supplementary information). This evidence concerns the gene SOAT1 and chronic obstructive pulmonary disease.